Wincal BioPharm

Wincal Biopharm is a private, preclinical-stage biotech company developing innovative ocular therapeutics. Its core assets are a proprietary Ocular Penetration Carrier (OPC) platform designed to enable topical eyedrop delivery of large-molecule drugs to the back of the eye, and a pipeline of next-generation anti-VEGF and tri-specific antibodies. The company aims to replace invasive intravitreal injections, with a lead program targeting a clinical trial initiation in 2027. Wincal is positioned in the large and growing market for retinal disease treatments, but faces significant technical and competitive risks inherent to novel drug delivery and development.

Proprietary Ocular Penetration Carrier (OPC) platform for in vivo screening of antibody:carrier pairs to enable topical eyedrop delivery of large-molecule therapeutics to the back of the eye. Also a multi-functional ocular disease screening platform for target ID and drug design.

The non-invasive ocular drug delivery space is highly competitive, with many companies exploring technologies like sustained-release implants, microneedles, and other topical formulations. Wincal must compete with these approaches and with established injectable therapies. Its success hinges on demonstrating superior or comparable efficacy with a vastly improved administration route.